MAIA Biotechnology, Inc. (NYSEAMERICAN:MAIA - Get Free Report)'s stock price fell 3.4% on Thursday . The stock traded as low as $2.36 and last traded at $2.57. 120,695 shares changed hands during trading, a decline of 59% from the average session volume of 292,118 shares. The stock had previously closed at $2.66.
MAIA Biotechnology Trading Down 2.3 %
The firm has a market cap of $60.01 million, a P/E ratio of -1.54 and a beta of 0.31.
MAIA Biotechnology (NYSEAMERICAN:MAIA - Get Free Report) last announced its quarterly earnings results on Friday, August 9th. The company reported ($0.17) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.33) by $0.16. As a group, analysts expect that MAIA Biotechnology, Inc. will post -1.25 earnings per share for the current fiscal year.
Institutional Inflows and Outflows
Several institutional investors and hedge funds have recently bought and sold shares of MAIA. Virtu Financial LLC bought a new stake in shares of MAIA Biotechnology during the 1st quarter valued at $71,000. Mather Group LLC. lifted its position in MAIA Biotechnology by 50,150.0% during the second quarter. Mather Group LLC. now owns 12,060 shares of the company's stock valued at $41,000 after purchasing an additional 12,036 shares in the last quarter. Finally, Ground Swell Capital LLC bought a new stake in MAIA Biotechnology during the second quarter valued at about $56,000. 5.65% of the stock is owned by hedge funds and other institutional investors.
MAIA Biotechnology Company Profile
(
Get Free Report)
MAIA Biotechnology, Inc, a clinical stage biotechnology company, engages in the discovery, development, and commercialization of therapies targeting cancer. The company's lead product candidate is THIO, a telomere-targeting agent that is in Phase II clinical study to evaluate its activity in patients with non-small cell lung cancer.
Featured Articles
Before you consider MAIA Biotechnology, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and MAIA Biotechnology wasn't on the list.
While MAIA Biotechnology currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link below to learn more about using beta to protect yourself.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
